Skip to main content

Table 2 Serum ceruloplasmin and 24 h urine copper in all patients with Wilson’s disease during treatment

From: Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson’s disease

Indicator

Time

Group 1 (N = 93)

Group 2 (N = 65/59)

P value

Serum ceruloplasmin (mg/L)

Baseline

79.34 ± 18.10

84.62 ± 15.75

0.648

8 weeks

82.24 ± 8.24

82.15 ± 15.89

0.965

1 year

81.75 ± 7.63

84.17 ± 9.18

0.147

24-h urinary copper (ug/24 h)

Baseline

393.23 ± 213.94

395.16 ± 225.27

0.956

2 weeks

1775.29 ± 665.92

1550.76 ± 540.06

0.026*

4 weeks

1509.21 ± 567.69

1598.01 ± 797.11

0.415

8 weeks

799.36 ± 279.42

874.01 ± 348.16

0.147

1 year

168.77 ± 80.72

176.69 ± 90.64

0.585

  1. Group 1: treated by sodium 2, 3-dimercapto-1-propane sulfonate in combination of zinc; Group 2: treated by D-penicillamine; Compared with Group 2, *P < 0.05; In Group 2: Baseline, 2 and 4 weeks: N = 65, 8 weeks and 1 year: N = 59